Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Classical hematology 1

Conditions

Febrile Neutropenia 6Neoplasms 4Neutropenia 2Hematologic Neoplasms 2Fever 2Sepsis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Myeloid, Acute 1Emergencies 1

Interventions

Cytarabine 11Idarubicin 6fludarabine 5venetoclax 4Granulocyte Colony-Stimulating Factor 4Azacitidine 4posaconazole 3fludarabine phosphate 2Micafungin 2Gemtuzumab 2Filgrastim 2Decitabine 2Daunorubicin 2ruxolitinib 1olutasidenib 1molgramostim 1eltrombopag 1aldesleukin 1aclacinomycins 1Transplantation, Homologous 1Topotecan 1Tobacco Use Cessation Devices 1Thiotepa 1Stem Cell Transplantation 1Safety 1Radiotherapy 1Psychiatric Rehabilitation 1Polymerase Chain Reaction 1Peripheral Blood Stem Cell Transplantation 1Panobinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Leukemia, Myeloid, Acute × Meropenem × Clear all
NCT05784844 2024-09-19

Antimicrobial Revision in Persistent Febrile Neutropenia

Wake Forest University Health Sciences

Phase 4 Withdrawn
Classical hematologyLymphoidOther hematologic neoplasm

Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Febrile Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡